Related Experiment Video
Updated: Aug 9, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.3K
Prognostic value of EIF5A2 in solid tumors: A meta-analysis and bioinformatics analysis
Jianwen Fang1, Tianze Yu1, Xiaocong Jiang1
1Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Open Medicine (Warsaw, Poland)
|May 21, 2024
Summary
Eukaryotic translation initiation factor 5A2 (EIF5A2) overexpression is linked to poor survival in many cancers. This study confirms EIF5A2 as a reliable prognostic biomarker for predicting cancer outcomes and patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genomics
Background:
- Aberrant overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) is associated with poor prognosis in cancer.
- EIF5A2 plays a critical role in promoting metastatic progression.
- EIF5A2 is recognized as a potential prognostic biomarker for various malignancies.
Purpose of the Study:
- To elucidate the utility and significance of EIF5A2 as a prognostic biomarker for cancer outcome prediction.
- To evaluate the prognostic value of EIF5A2 in solid tumors.
- To assess the efficacy of EIF5A2 as a predictive marker for cancer.
Main Methods:
- A comprehensive literature search was conducted across PubMed, EMBASE, and Web of Science databases.
- Meta-analysis was performed to examine the association between EIF5A2 and survival prognosis using hazard ratios and 95% confidence intervals.
- The Cancer Genome Atlas (TCGA) and Gene Expression Profiling Interactive Analysis (GEPIA) databases were utilized for validation of EIF5A2 expression and its correlation with patient outcomes across diverse cancer types.
Main Results:
- Pooled analysis revealed that increased EIF5A2 expression significantly correlates with decreased overall survival (OS) and disease-free survival/progression-free survival/relapse-free survival (DFS/PFS/RFS).
- TCGA data indicated significant upregulation of EIF5A2 in 27 cancer types, with overexpression linked to shorter OS, worse DFS, and worse PFS in specific cancer subtypes.
- GEPIA analysis further supported that EIF5A2 overexpression is associated with reduced OS and DFS.
Conclusions:
- EIF5A2 is validated as a reliable prognostic marker in solid tumors.
- The meta-analysis confirms the significant prognostic value of EIF5A2 in predicting patient survival across various solid malignancies.
- EIF5A2 demonstrates efficacy as a predictive marker for cancer outcomes.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...